PuSH - Publikationsserver des Helmholtz Zentrums München

Novikoff, A. ; Müller, T.D.

One small molecule for man, one giant leap for mankind with obesity.

Med. 6:100924 (2025)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
The ATTAIN-1 trial launches a new era in obesity care. Orforglipron, the first oral small-molecule GLP-1 receptor agonist to complete a phase 3 clinical trial, delivers meaningful reductions in body weight and improvements in metabolic health. This advancement moves beyond peptide-based injectables, paving the way for potent obesity therapies that are simpler, more affordable, and accessible to millions worldwide.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Editorial
ISSN (print) / ISBN 2666-6359
e-ISSN 2666-6340
Zeitschrift Med (N Y)
Quellenangaben Band: 6, Heft: 12, Seiten: , Artikelnummer: 100924 Supplement: ,
Verlag Elsevier
Verlagsort 50 Hampshire St, Floor 5, Cambridge, Ma 02139 Usa
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Obesity (IDO)
Förderungen German Center for Diabetes Research (DZD e.V.)
German Research Foundation
European Union within European Research Council ERC-CoG